S L Berg

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates
    Stacey L Berg
    Texas Children s Cancer Center, 6621 Fannin Street, MC3 3320, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 59:743-7. 2007
  2. ncbi request reprint Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer
    Murali Chintagumpala
    Texas Children s Cancer Center, 6621 Fannin, MC 3 3320, Houston, TX 77030, USA
    J Clin Oncol 22:4394-400. 2004
  3. ncbi request reprint Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group
    Stacey L Berg
    Texas Children s Cancer Center, Baylor College of Medicine, 6621 Fannin St, MC3 3320, Houston, TX 77030, USA
    J Clin Oncol 23:3376-82. 2005
  4. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates
    Stacey L Berg
    Texas Children s Cancer Center, Department of Pediatrics, Baylor College of Medicine, 6621 Fannin, MC 33320, Houston 77030, USA
    Cancer Chemother Pharmacol 54:127-30. 2004
  5. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates
    Stacey L Berg
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 54:85-8. 2004
  6. ncbi request reprint Ethical challenges in cancer research in children
    Stacey L Berg
    Texas Children s Cancer Center, 6621 Fannin Street, MC3 3320, Houston, Texas 77030, USA
    Oncologist 12:1336-43. 2007
  7. pmc Reasons for participation in optional pharmacokinetic studies in children with cancer: a Children's Oncology Group phase 1 consortium study
    Stacey L Berg
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Pediatr Blood Cancer 55:119-22. 2010
  8. ncbi request reprint Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate
    S Berg
    Texas Children s Cancer Center and Texas Children s Hospital, Baylor College of Medicine, Houston, TX, USA
    Cancer Chemother Pharmacol 47:385-90. 2001
  9. ncbi request reprint Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group phase II study
    S L Berg
    Texas Children s Cancer Center, Houston 77030, USA
    J Pediatr Hematol Oncol 22:506-9. 2000
  10. pmc Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report
    Stacey L Berg
    Texas Children s Cancer Center, 6621 Fannin St, MC3 3320, Houston, TX 77030, USA
    J Clin Oncol 29:316-23. 2011

Detail Information

Publications36

  1. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates
    Stacey L Berg
    Texas Children s Cancer Center, 6621 Fannin Street, MC3 3320, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 59:743-7. 2007
    ..We therefore studied the CSF penetration of nelarabine and ara-G in a nonhuman primate model that has been highly predictive of anticancer drug distribution in humans...
  2. ncbi request reprint Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer
    Murali Chintagumpala
    Texas Children s Cancer Center, 6621 Fannin, MC 3 3320, Houston, TX 77030, USA
    J Clin Oncol 22:4394-400. 2004
    ..Recent studies have indicated that thalidomide inhibits angiogenesis. We performed a phase I and pharmacokinetic study of thalidomide with carboplatin in children with refractory solid tumors...
  3. ncbi request reprint Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group
    Stacey L Berg
    Texas Children s Cancer Center, Baylor College of Medicine, 6621 Fannin St, MC3 3320, Houston, TX 77030, USA
    J Clin Oncol 23:3376-82. 2005
    ..We sought to define the response rate of nelarabine in children and young adults with refractory or recurrent T-cell disease...
  4. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates
    Stacey L Berg
    Texas Children s Cancer Center, Department of Pediatrics, Baylor College of Medicine, 6621 Fannin, MC 33320, Houston 77030, USA
    Cancer Chemother Pharmacol 54:127-30. 2004
    ..We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics of NSC 655649 after systemic administration in a nonhuman primate model that is predictive of anticancer drug behavior in humans...
  5. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates
    Stacey L Berg
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 54:85-8. 2004
    ..We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics of depsipeptide in a nonhuman primate model that is highly predictive of human CSF penetration...
  6. ncbi request reprint Ethical challenges in cancer research in children
    Stacey L Berg
    Texas Children s Cancer Center, 6621 Fannin Street, MC3 3320, Houston, Texas 77030, USA
    Oncologist 12:1336-43. 2007
    ..It is important for researchers and clinicians to understand these challenges so that progress in cancer treatment is achieved in a sound ethical and regulatory fashion...
  7. pmc Reasons for participation in optional pharmacokinetic studies in children with cancer: a Children's Oncology Group phase 1 consortium study
    Stacey L Berg
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Pediatr Blood Cancer 55:119-22. 2010
    ..In the Children's Oncology Group (COG) Phase 1 Consortium, pharmacokinetic studies are usually optional. We surveyed the attitudes towards PK studies among subjects in phase 1 trials at COG institutions...
  8. ncbi request reprint Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate
    S Berg
    Texas Children s Cancer Center and Texas Children s Hospital, Baylor College of Medicine, Houston, TX, USA
    Cancer Chemother Pharmacol 47:385-90. 2001
    ..We studied the pharmacokinetics, metabolism, and cerebrospinal fluid (CSF) penetration of PA and PB after intravenous (i.v.) administration in the nonhuman primate...
  9. ncbi request reprint Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group phase II study
    S L Berg
    Texas Children s Cancer Center, Houston 77030, USA
    J Pediatr Hematol Oncol 22:506-9. 2000
    ..The Pediatric Oncology Group conducted a phase II study to determine the activity of PZA administered as a 3-hour infusion...
  10. pmc Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report
    Stacey L Berg
    Texas Children s Cancer Center, 6621 Fannin St, MC3 3320, Houston, TX 77030, USA
    J Clin Oncol 29:316-23. 2011
    ....
  11. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates
    J Z Kerr
    Texas Children's Cancer Center, Baylor College of Medicine, 6621 Fannin Street, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 47:411-4. 2001
    ....
  12. ncbi request reprint A phase I study of irinotecan in pediatric patients: a pediatric oncology group study
    S Blaney
    Texas Children s Cancer Center Baylor College of Medicine, Houston 77030, USA
    Clin Cancer Res 7:32-7. 2001
    ..In conclusion, the recommended Phase II dose of irinotecan administered as a 60-min i.v. infusion daily for 5 days, every 21 days, is 39 mg/m2 in heavily treated and 50 mg/m2 in less-heavily treated children with solid tumors...
  13. ncbi request reprint Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers
    S L Berg
    Texas Children s Cancer Center, Texas Children s Hospital and Baylor College of Medicine, Houston 77030, USA
    J Clin Oncol 16:181-6. 1998
    ....
  14. ncbi request reprint The development of camptothecin analogs in childhood cancers
    L Bomgaars
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas, USA
    Oncologist 6:506-16. 2001
    ..These and future planned studies of this novel class of cytotoxic agents are critical to defining the ultimate role of topoisomerase I poisons in the treatment of childhood cancer...
  15. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates
    Stacey L Berg
    Texas Children s Cancer Center, Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 11:5981-3. 2005
    ..We studied the pharmacokinetics and cerebrospinal fluid penetration of clofarabine in a nonhuman primate model...
  16. ncbi request reprint Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis
    L Bomgaars
    Texas Children s Cancer Center Baylor College of Medicine, 6621 Fannin, MC 3 3320, Houston, TX 77030, USA
    J Clin Oncol 22:3916-21. 2004
    ....
  17. ncbi request reprint Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015)
    Susan M Blaney
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 22:4804-9. 2004
    ..To determine the maximum-tolerated dose, dose-limiting toxicity (DLT), and pharmacodynamics of the proteasome inhibitor bortezomib (formerly PS-341) in children with recurrent or refractory solid tumors...
  18. pmc Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity
    Terzah M Horton
    Texas Children s Cancer Center Baylor College of Medicine, Houston, Texas 77030, USA
    Mol Cancer Ther 8:2232-42. 2009
    ..In conclusion, although ABT-888 potentiation of TMZ was most pronounced in MMR-deficient cells with low MGMT activity, neither MMR proficiency nor MGMT overexpression completely abrogated ABT-888 potentiation of TMZ...
  19. doi request reprint Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates
    Lindsay B Kilburn
    Texas Children s Cancer Center, Baylor College of Medicine, 6621 Fannin St, MC 3 3320, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 64:335-40. 2009
    ..To evaluate the plasma and cerebrospinal fluid (CSF) pharmacokinetics and CSF penetration of tasidotin and metabolites in a nonhuman primate model...
  20. doi request reprint Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study
    Patrick A Thompson
    Texas Children s Cancer Center, 6621 Fannin St, MC3 3320, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 64:243-51. 2009
    ..We studied the relationship between doxorubicin pharmacokinetics and body composition in children with cancer...
  21. ncbi request reprint Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study
    Terzah M Horton
    Texas Children s Cancer Center Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Oncol 25:4922-8. 2007
    ..To determine the tolerability, pharmacokinetics, and mechanisms of temozolomide resistance in children with relapsed or refractory leukemia...
  22. doi request reprint Educational paper. The development of new therapies for pediatric oncology
    Terzah M Horton
    Texas Children s Cancer Center, Baylor College of Medicine, 1102 Bates, Suit 750, Houston, TX 77030, USA
    Eur J Pediatr 170:555-9. 2011
    ....
  23. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates
    Stacie L Stapleton
    Texas Children s Cancer Center Baylor College of Medicine, 6621 Fannin, CC 1410 00, Houston, TX, 77030, USA
    Cancer Chemother Pharmacol 61:647-52. 2008
    ....
  24. ncbi request reprint Bortezomib interactions with chemotherapy agents in acute leukemia in vitro
    Terzah M Horton
    Texas Children s Cancer Center Baylor College of Medicine, 6621 Fannin, MC 3 3320, Houston, 77030, USA
    Cancer Chemother Pharmacol 58:13-23. 2006
    ..These data suggest bortezomib could potentiate the cytotoxic effects of combination chemotherapy in patients with leukemia...
  25. ncbi request reprint Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study
    Terzah M Horton
    University of Texas Health Science Center, San Antonio, TX, USA
    Clin Cancer Res 11:1884-9. 2005
    ..To evaluate the toxicity, antileukemic activity, and pharmacology of raltitrexed administered weekly for 3 weeks to patients with refractory or recurrent leukemia...
  26. ncbi request reprint Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate
    S L Berg
    Texas Children s Cancer Center, Texas Children s Hospital, Baylor College of Medicine, Houston 77030, USA
    Clin Cancer Res 4:2891-4. 1998
    ..We concluded that intrathecal administration of O6BG is well tolerated in the nonhuman primate and seems to have a substantial pharmacokinetic advantage over systemic administration for meningeal tumors...
  27. pmc Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines
    Eufemia Jacob
    Texas Children s Cancer Center, Texas Children s Hospital, Baylor College of Medicine, Houston, Texas, USA
    Pediatr Blood Cancer 50:757-60. 2008
    ..The purpose of this study was to determine the cytotoxic effects of karenitecin and mafosfamide in vitro against leukemia, medulloblastoma, and neuroblastoma cell lines...
  28. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates
    Patrick A Thompson
    Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 53:527-32. 2004
    ..This study was undertaken to define the pharmacokinetics of BNP1350 in both plasma and cerebrospinal fluid (CSF) in a nonhuman primate model...
  29. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates
    Kathleen Neville
    Texas Children s Cancer Center, Houston, 77030, USA
    Clin Cancer Res 10:2525-9. 2004
    ..We used a nonhuman primate model that is highly predictive of the cerebrospinal fluid penetration of drugs in humans to study the pharmacokinetics of imatinib in plasma and cerebrospinal fluid (CSF) after i.v. and p.o. administration...
  30. ncbi request reprint Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis
    Ronald J Bernardi
    Texas Children s Hospital, Baylor College of Medicine, Houston, TX, 77030, USA
    Cancer Chemother Pharmacol 62:355-61. 2008
    ....
  31. ncbi request reprint Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis
    Stacey L Berg
    Department of Pediatric Oncology, Texas Children s Cancer Center, Baylor College of Medicine, USA
    Curr Oncol Rep 5:29-40. 2003
    ..This article outlines the role of systemic and intrathecal chemotherapy in patients with leptomeningeal metastases. Strategies for symptom management in these patients are also described...
  32. ncbi request reprint Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia
    Patrick A Thompson
    Texas Children s Cancer Center, Baylor College of Medicine, 6621 Fannin St MC, Houston, TX 77030 2399, USA
    Cancer Chemother Pharmacol 59:847-53. 2007
    ....
  33. ncbi request reprint Current treatment of leptomeningeal metastases: systemic chemotherapy, intrathecal chemotherapy and symptom management
    Stacey L Berg
    Norris Cancer Center, University of Southern California, Los Angeles, CA 90089, USA
    Cancer Treat Res 125:121-46. 2005
    ..As the majority of patients have widespread incurable systemic tumor, treatment is predominantly palliative; however, some patients with leukemia, lymphoma or breast cancer may have prolonged remissions and the possibility of cure...
  34. ncbi request reprint Pharmacokinetics of intrathecal gemcitabine in nonhuman primates
    Merrill J Egorin
    Department of Pharmacology, and Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 8:2437-42. 2002
    ..We quantified cerebrospinal fluid (CSF) and plasma concentrations of gemcitabine and its inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU), in nonhuman primates given intrathecal gemcitabine...
  35. ncbi request reprint Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study
    Denise M Adams
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA
    Pediatr Blood Cancer 50:549-53. 2008
    ....
  36. doi request reprint Characteristics and outcome of pediatric patients enrolled in phase I oncology trials
    Aerang Kim
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Building 10 CRC, Room 1 3872, Bethesda, MD 20892, USA
    Oncologist 13:679-89. 2008
    ..To describe the characteristics of pediatric subjects who enroll in phase I trials, to determine the associations between pre-enrollment characteristics and the risk for toxicity, and to analyze response and survival outcomes...